Previous clinical trials demonstrated that treatment of SLE patients with low-dose IL-2 promoted regulatory T (Treg) cells and inhibited TH17 cells and was associated with the induction of remission114,115. This evidence concerns the gene IL2 and systemic lupus erythematosus.